• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » Google renames life sciences biz to ‘Verily’

Google renames life sciences biz to ‘Verily’

December 8, 2015 By Fink Densford

Verily

Google (NSDQ:GOOG) parent company Alphabet said yesterday that it renamed its life sciences division to ‘Verily’, presenting a mission of ‘understanding disease on an individual level’ with a focus on prevention and proactive solutions.

The name change comes as the company seeks more visibility in the med-tech world.

“Our mission is to bring together technology and life sciences to uncover new truths about health and disease,” according to Verily’s website.

CEO Andy Conrad, who will stay head of the newly named business, said the name is meant to be aspirational. “Only through the truth are we going to defeat Mother Nature,” Conrat told STAT.  The word itself means ‘truly’ or ‘certainly’.

Verily was previously part of Google X, the company’s experimental laboratory. In August, Google restructured and put the life sciences biz under its new umbrella parent company, Alphabet.

Even before its reorganization and new moniker, the Google department has been hard at work.

Last year, the life sciences business under Google announced a partnership with Novartis‘ (NYSE:NVS) Alcon subsidiary to develop a “smart” contact lenses that can measure blood glucose levels and transmit reports wirelessly.

“We hope this smart contact lens will make it easier for people with diabetes to monitor themselves continuously by measuring the glucose in their tears,” the company writes on its website.

In August, the life sciences biz at Google signed a partnership deal with Dexcom Inc. (NSDQ:DXCM) to jointly develop continuous glucose monitoring products.

The partnership will bring together Google’s miniaturized electronics platform and DexCom’s sensor technology, and looks to develop next-generation CGM devices that will be less expensive than existing technologies, San Diego, Calif.-based DexCom said.

Verily’s research team is also undertaking a multi-year project, known as the Baseline study, that aims to identify traits associated with a healthy human and the changes that take place as individuals transition from health to disease.

Material from Reuters was used in this report.

Filed Under: Business/Financial News Tagged With: Alphabet (Google), Verily

More recent news

  • EBR Systems raises $36.1M for leadless pacing tech
  • The biggest cardiovascular tech news out of EuroPCR 2025
  • CardiaWave has positive 12-month Valvosoft results
  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Medtronic has new Cardiovascular, CST leaders after longtime exec departs

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy